Kaczmarek, RadoslawPiñeros, Annie R.Patterson, Paige E.Bertolini, Thais B.Perrin, George Q.Sherman, AlexandraBorn, JamesonArisa, SreevaniArvin, Matthew C.Kamocka, Malgorzata M.Martinez, Michelle M.Dunn, Kenneth W.Quinn, Sean M.Morris, Johnathan J.Wilhelm, Amelia R.Kaisho, TsuneyasuMunoz-Melero, MaiteBiswas, MoanaroKaplan, Mark H.Linnemann, Amelia K.George, Lindsey A.Camire, Rodney M.Herzog, Roland W.2024-02-092024-02-092023Kaczmarek R, Piñeros AR, Patterson PE, et al. Factor VIII trafficking to CD4+ T cells shapes its immunogenicity and requires several types of antigen-presenting cells. Blood. 2023;142(3):290-305. doi:10.1182/blood.2022018937https://hdl.handle.net/1805/38372Despite >80 years of clinical experience with coagulation factor VIII (FVIII) inhibitors, surprisingly little is known about the in vivo mechanism of this most serious complication of replacement therapy for hemophilia A. These neutralizing antidrug alloantibodies arise in ∼30% of patients. Inhibitor formation is T-cell dependent, but events leading up to helper T-cell activation have been elusive because of, in part, the complex anatomy and cellular makeup of the spleen. Here, we show that FVIII antigen presentation to CD4+ T cells critically depends on a select set of several anatomically distinct antigen-presenting cells, whereby marginal zone B cells and marginal zone and marginal metallophilic macrophages but not red pulp macrophages (RPMFs) participate in shuttling FVIII to the white pulp in which conventional dendritic cells (DCs) prime helper T cells, which then differentiate into follicular helper T (Tfh) cells. Toll-like receptor 9 stimulation accelerated Tfh cell responses and germinal center and inhibitor formation, whereas systemic administration of FVIII alone in hemophilia A mice increased frequencies of monocyte-derived and plasmacytoid DCs. Moreover, FVIII enhanced T-cell proliferation to another protein antigen (ovalbumin), and inflammatory signaling-deficient mice were less likely to develop inhibitors, indicating that FVIII may have intrinsic immunostimulatory properties. Ovalbumin, which, unlike FVIII, is absorbed into the RPMF compartment, fails to elicit T-cell proliferative and antibody responses when administered at the same dose as FVIII. Altogether, we propose that an antigen trafficking pattern that results in efficient in vivo delivery to DCs and inflammatory signaling, shape the immunogenicity of FVIII.en-USAttribution-NonCommercial-NoDerivatives 4.0 InternationalFactor VIIIHemostaticsHemophilia AOvalbuminArticle